226950.KQ
OliX Pharmaceuticals,Inc
KOE · Healthcare · Biotechnology · KR
KRW 91,800.00
−8.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 13.6B | 14.7B | 5.7B | 17.1B | 9.3B |
| Cost of Revenue | 2.3B | 2.5B | 2.6B | 2.6B | 2.0B |
| Gross Profit | 11.9B | 14.7B | 3.1B | 14.4B | 7.3B |
| Operating Expenses | |||||
| R&D Expense | 31.5B | 25.6B | 19.5B | 18.5B | 17.4B |
| SG&A Expense | 9.9B | 4.3B | 3.5B | 3.7B | 2.9B |
| General & Admin Expense | 989.6M | 1.2B | 918.6M | 1.0B | 862.2M |
| Selling & Marketing Expense | 2.8B | 3.1B | 2.6B | 2.7B | 2.0B |
| Other Expenses | 20.6B | 14.7B | 10.9B | 10.5B | 9.5B |
| Total Operating Expenses | 53.4B | 44.6B | 34.0B | 32.7B | 29.7B |
| Cost and Expenses | 55.2B | 44.6B | 36.6B | 35.2B | 31.7B |
| Operating Income (EBIT) | (41.6B) | (30.0B) | (30.9B) | (18.2B) | (22.4B) |
| Non-Operating | |||||
| Interest Income | 2.3B | 1.0B | 433.8M | 1.3B | 1.4B |
| Interest Expense | 1.1B | 1.8B | 4.7B | 3.5B | 2.9B |
| Net Interest Income | 1.2B | (770.0M) | (4.2B) | (2.2B) | (1.5B) |
| Other Non-Op Income/Expense | 27.6B | 16.7B | (10.2B) | 15.7M | (6.7B) |
| Non-Operating Income (excl Interest) | (24.2B) | — | 2.4B | (3.5B) | 3.8B |
| EBT (Pre-Tax Income) | (13.9B) | (13.3B) | (41.1B) | (18.2B) | (29.1B) |
| Income Tax Expense | 128.0M | 2.5B | (412.0M) | 932.1M | (994.9M) |
| Bottom Line | |||||
| Net Income | (14.0B) | (16.2B) | (40.7B) | (19.1B) | (19.5B) |
| Earnings from Cont. Ops | (14.0B) | (16.2B) | (40.1B) | (19.1B) | (28.1B) |
| Earnings from Discont. Ops | — | — | — | — | 6.2B |
| Bottom Line Net Income | (14.0B) | (16.2B) | (40.7B) | (19.1B) | (19.5B) |
| Per Share | |||||
| Basic EPS | (₩603) | (₩804) | (₩2,403) | (₩1,324) | (₩1,423) |
| Diluted EPS | (₩603) | (₩804) | (₩2,403) | (₩1,324) | (₩1,423) |
| Revenue Per Share | ₩611 | ₩726 | ₩337 | ₩1,183 | ₩680 |
| Shares | |||||
| Basic Shares Outstanding | 22.3M | 20.2M | 16.8M | 14.4M | 13.7M |
| Diluted Shares Outstanding | 22.3M | 20.2M | 16.8M | 14.4M | 13.7M |
| Profitability Metrics | |||||
| EBITDA | (39.2B) | (27.5B) | (28.3B) | (15.5B) | (24.2B) |
| D&A | 2.3B | 2.5B | 2.6B | 2.6B | 2.0B |
| EBIT | (41.6B) | (30.0B) | (30.9B) | (18.2B) | (26.2B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026